LONDON, June 9, 2016 /PRNewswire/ --
Published recently in European Journal of Arrhythmia & Electrophysiology, the peer-reviewed journal from touchCARDIO, José Silva Cardoso discusses the important findings from the PARADIGM-HF study. This study indicated that the angiotensin receptorneprilysin inhibitor, LCZ696, is superior to enalapril in reducing the risks of cardiovascular death and of hospitalisation for heart failure in patients with heart failure and reduced ejection fraction.
The full peer-reviewed, open-access article is available here:
Disclosure: José Silva Cardoso has consulted and received speaker fees and investigational grants from Novartis. He was the National Coordinator of PARADIGM-HF for Portugal. This article is a short opinion piece and has not been submitted to external peer reviewers, but was reviewed by the Editorial Board before publication.
touchCARDIO (a division of Touch Medical Media) publishesEuropean Journal of Arrhythmia & Electrophysiologyy, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of cardiology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.
For inquires please contact:
Nicola Cartridge - Managing Editor
Providing practical opinion to support best practice for busy healthcare professionals.